Portola announces interim results from ongoing phase 3b/4 ANNEXXA-4TM study
Portola Pharmaceuticals announced interim results from the ongoing Phase 3b/4 ANNEXA™-4 study of AndexXa™ (andexanet alfa), a Factor Xa inhibitor antidote. The interim results were published online by The New England Journal of Medicine.
August 30, 2016